Literature DB >> 23823827

Device related complications of the Coflex interspinous process implant for the lumbar spine.

Lei Zang1, Peng DU, Yong Hai, Qing-jun Su, Shi-bao Lu, Tie Liu.   

Abstract

BACKGROUND: Coflex, a type of interspinous process implant, can provide intervertebral dynamic stability for surgical segments and effectively relieve lumbocrural pain. However, few studies have described therapeutic strategies and the avoidance of Coflex implant complications.
METHODS: Coflex implant complications in this study included intraoperative or postoperative spinous process fracture, aggravated postoperative lumbocrural pain, dislodgment and malposition. The complications were analyzed, and therapeutic strategies were applied according to the specific complication. The Visual Analogue Scale and Oswestry Disability Index scores were evaluated by using the paired-samples test from SPSS 12.0.
RESULTS: Conservative treatment was provided to seven patients who experienced aggravated lumbocrural pain even though their devices remained in the correct position, and pedicle screw treatment was used as an alternative in four cases. The Visual Analogue Scale and Oswestry Disability Index scores showed evident improvement in these patients. The Visual Analogue Scale and Oswestry Disability Index scores of two patients who underwent revision were also improved.
CONCLUSIONS: Coflex implants should be avoided in patients with osteoporosis, a narrow interspinous space and intervertebral coronal spondylolysis, or sagittal instability. Furthermore the device choice, depth of implantation, and clamping intensity should be appropriate. Conservative treatment can be provided to patients with symptoms if the device remains in the correct position; however, revisions and salvages should be undertaken with internal fixation of pedicle screws for patients with device malposition, intraoperative implantation failure, or device intolerance.

Entities:  

Mesh:

Year:  2013        PMID: 23823827

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

1.  Interspinous posterior devices: What is the real surgical indication?

Authors:  Alessandro Landi
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

2.  Interspinous dynamic stabilization adjacent to fusion versus double-segment fusion for treatment of lumbar degenerative disease with a minimum follow-up of three years.

Authors:  Xiao-Long Chen; Li Guan; Yu-Zeng Liu; Jin-Cai Yang; Wen-Long Wang; Yong Hai
Journal:  Int Orthop       Date:  2016-04-27       Impact factor: 3.075

3.  Superior outcomes of decompression with an interlaminar dynamic device versus decompression alone in patients with lumbar spinal stenosis and back pain: a cross registry study.

Authors:  C Röder; B Baumgärtner; U Berlemann; E Aghayev
Journal:  Eur Spine J       Date:  2015-07-18       Impact factor: 3.134

4.  The cost effectiveness of dynamic and static interspinous spacer for lumbar spinal stenosis compared with laminectomy.

Authors:  Mohsen Yaghoubi; Maziar Moradi-Lakeh; Mohammad Moradi-Joo; Vafa Rahimi-Movaghar; Neda Zamani; Ahmad Naghibzadeh-Tahami
Journal:  Med J Islam Repub Iran       Date:  2016-03-06

5.  Topping-Off Technology versus Posterior Lumbar Interbody Fusion in the Treatment of Lumbar Disc Herniation: A Meta-Analysis.

Authors:  Wei Wang; Xiangyao Sun; Tongtong Zhang; Siyuan Sun; Chao Kong; Shibao Lu
Journal:  Biomed Res Int       Date:  2020-01-13       Impact factor: 3.411

6.  Interlaminar stabilization offers greater biomechanical advantage compared to interspinous stabilization after lumbar decompression: a finite element analysis.

Authors:  Teng Lu; Yi Lu
Journal:  J Orthop Surg Res       Date:  2020-07-29       Impact factor: 2.359

7.  Comparison between topping-off technology and posterior lumbar interbody fusion in the treatment of chronic low back pain: A meta-analysis.

Authors:  Wei Wang; Xiangyao Sun; Tongtong Zhang; Siyuan Sun; Chao Kong; Junzhe Ding; Xiangyu Li; Shibao Lu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.